FACTOCEL VIII 250IU INJECTION

FACTOCEL VIII 250IU INJECTION can be derived from human plasma, which undergoes a purification process or is produced using recombinant DNA technology

Yes, FACTOCEL VIII 250IU INJECTION can be used in children. The dosage and administration may vary based on the child's age, weight, and needs. Pediatric patients with hemophilia A can benefit from regular treatment with this drug to prevent and manage bleeding episodes.

The most common side effect of FACTOCEL VIII 250IU INJECTION is the development of inhibitors (antibodies) that can interfere with the effectiveness of the treatment. Other possible side effects include allergic reactions, infusion site reactions, and the risk of blood clots.

FACTOCEL VIII 250IU INJECTION is administered intravenously (IV) through a needle inserted into a vein by your physician in a hospital setting. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.

FACTOCEL VIII 250IU INJECTION can be used before surgery or dental procedures in individuals with hemophilia A to prevent excessive bleeding. Coordinating with the healthcare team is important to ensure proper dosing and timing.

There is no known interaction of FACTOCEL VIII 250IU INJECTION with other drugs.

If you regularly or repeatedly receive human plasma-derived FACTOCEL VIII 250IU INJECTION products, your doctor may recommend vaccination against hepatitis A and B. It is because there is a possible risk of exposure to these viruses through plasma-derived products. Vaccination can help protect against these infections. Good dental hygiene is important to maintain oral health and prevent tooth and gum disease. It is particularly relevant for individuals with bleeding disorders such as hemophilia A, as they may be more susceptible to excessive bleeding. If you notice any changes in your symptoms or have concerns about the treatment with FACTOCEL VIII 250IU INJECTION, immediately communicate them to your physician for more advice.

Factor VIII is a molecule used for making FACTOCEL VIII 250IU INJECTION. It is an essential blood-clotting protein that is missing or reduced in people with hemophilia A.

FACTOCEL VIII 250IU INJECTION is primarily prescribed for the treatment of Hemophilia A, a bleeding disorder affecting blood's ability to clot.